Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2

Archives of Virology

Volumn 153, Issue 6, 2008, Pages 1165-1169

  Muller, William J ^a,g   Orgun, Nural N ^b   Dong, Lichun ^c   Koelle, David M ^c,d,e   Huang, Meei Li ^c   Way, Sing Sing ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN B, HERPES SIMPLEX VIRUS TYPE 2; HERPES SIMPLEX VACCINE; RECOMBINANT VACCINE; T LYMPHOCYTE RECEPTOR; VIRUS ENVELOPE PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CD8+ T LYMPHOCYTE; FEMALE; GENETIC RECOMBINATION; GENETICS; GENITAL HERPES; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LISTERIA MONOCYTOGENES; METABOLISM; MOUSE; VACCINATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMMUNODOMINANT EPITOPES; INJECTIONS, INTRAVENOUS; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED C57BL; RECOMBINATION, GENETIC; SIMPLEXVIRUS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; LISTERIA MONOCYTOGENES; MUS; SIMPLEXVIRUS;

EID: 44449103056     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-008-0089-7     Document Type: Article

References (30)

1. Blaney JJ, Nobusawa E, Brehm M, Bonneau R, Mylin L, Fu T, Kawaoka Y, Tevethia S (1998) Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J Virol 72:9567-9574
2. Bonneau R, Salvucci L, Johnson D, Tevethia S (1993) Epitope specificity of H-2 Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology 195:62-70
3. Corey L, Langenberg A, Ashley R, Sekulovich R, Izu A, Douglas JJ, Handsfield H, Warren T, Marr L, Tyring S, DiCarlo R, Adimora A, Leone P, Dekker C, Burke R, Leong W, Straus S (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282:331-340
4. Corey L (2005) Herpes simplex virus. In: Mandell G, Bennett J, Dolin R (eds) Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia
5. Dolan A, Jamieson F, Cunningham C, Barnett B, McGeoch D (1998) The genome sequence of herpes simplex virus type 2. J Virol 72:2010-2021
6. Gallichan W, Rosenthal K (1996) Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 184:1879-1890
7. Gallichan W, Rosenthal K (1996) Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology 224:487-497
8. Gierynska M, Kumaraguru U, Eo S-K, Lee S, Krieg A, Rouse B (2002) Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol 76:6568-6576
9. Hamilton S, Badovinac V, Khanolkar A, Harty J (2006) Listeriolysin O-deficient Listeria monocytogenes as a vaccine delivery vehicle: antigen-specific CD8 T cell priming and protective immunity. J Immunol 177:4012-4020
10. Khanna K, Bonneau R, Kinchington P, Hendricks R (2003) Herpes simplex virus-specific memory CD8 + T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18:593-603
11. Koelle D, Posavad C, Barnum G, Johnson M, Frank J, Corey L (1998) Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 101:1500-1508
12. Koelle D, Liu Z, McClurkan C, Topp M, Riddell S, Pamer E, Johnson A, Wald A, Corey L (2002) Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 110:537-548
13. Koelle D, Corey L (2003) Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16:96-113
14. Koelle D, Gonzalez J, Johnson A (2005) Homing in on the cellular immune response to HSV-2 in humans. Am J Reprod Immunol 53:172-181
15. Kollmann T, Reikie B, Blimkie D, Way S, Hajjar A, Arispe K, Shaulov A, Wilson C (2007) Induction of protective immunity to Listeria monocytogenes in neonates. J Immunol 178:3695-3701
16. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse B (1997) Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 71:3138-3145
17. Kumaraguru U, Gierynska M, Norman S, Bruce B, Rouse B (2002) Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J Virol 76:136-141
18. Orr M, Orgun N, Wilson C, Way S (2007) Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 178:4731-4735
19. Park SF, Stewart GS (1990) High-efficiency transformation of Listeria monocytogenes by electroporation of penicillin-treated cells. Gene 94:129-132
20. Parr E, Parr M (1997) Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J Virol 71:8109-8115
21. Parr M, Kepple L, McDermott M, Drew M, Bozzola J, Parr E (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70:369-380
22. Ryncarz A, Goddard J, Wald A, Huang M, Roizman B, Corey L (1999) Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 37:1941-1947
23. Shiver J, Emini E (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55:355-372
24. Stanberry L (2004) Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11:161A-169A
25. Starks H, Bruhn K, Shen H, Barry R, Dubensky T, Brockstedt D, Hinrichs D, Higgins D, Miller J, Giedlin M, Bouwer H (2004) Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy. J Immunol 173:420-427
26. Stock A, Jones C, Heath W, Carbone F (2006) CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant. Immunol Cell Biol 84:543-550
27. Verjans G, Hintzen R, van Dun J, Poot A, Milikan J, Laman J, Langerak A, Kinchington P, Osterhaus A (2007) Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci USA 104:3496-3501
28. Wald A, Huang M, Carrell D, Selke S, Corey L (2003) Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188:1345-1351
29. Wallace M, Keating R, Heath W, Carbone F (1999) The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 73:7619-7626
30. Zhu J, Koelle D, Cao J, Vazquez J, Huang M, Hladik F, Wald A, Corey L (2007) Virus-specific CD8 + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204:595-603